REVIEW
|
doi:10.20944/preprints202307.2062.v1
Subject:
Medicine And Pharmacology,
Clinical Medicine
Keywords:
gene editing; gene therapy; FDA; regulatory approval
Online: 31 July 2023 (04:55:07 CEST)
REVIEW
|
doi:10.20944/preprints202111.0384.v1
Subject:
Medicine And Pharmacology,
Gastroenterology And Hepatology
Keywords:
Alcohol abuse; cell signaling; FDA-approved drugs; oxidative stress; therapy
Online: 22 November 2021 (11:41:50 CET)
REVIEW
Subject:
Chemistry And Materials Science,
Medicinal Chemistry
Keywords:
cannabis; cannabinergic; drug; FDA-approved; medical conditions; pharmaceutical-grade; phytocannabinoid
Online: 31 August 2020 (10:38:32 CEST)
ARTICLE
|
doi:10.20944/preprints202407.0872.v1
Subject:
Biology And Life Sciences,
Aquatic Science
Keywords:
Improved multiplex PCR; U.S; FDA BAM; tlh; trh; tdh; Vibrio parahaemolyticus
Online: 11 July 2024 (10:22:28 CEST)
ARTICLE
Subject:
Biology And Life Sciences,
Virology
Keywords:
Ebola virus; rhesus macaque; animal model; FDA Animal Rule; natural history
Online: 5 February 2021 (11:34:20 CET)
COMMUNICATION
|
doi:10.20944/preprints202004.0062.v1
Subject:
Medicine And Pharmacology,
Epidemiology And Infectious Diseases
Keywords:
COVID-19; FDA approved drugs; High Throughput Virtual Screening; Sincalide; Pentagastrin.
Online: 6 April 2020 (14:09:04 CEST)
REVIEW
|
doi:10.20944/preprints202405.0326.v1
Subject:
Medicine And Pharmacology,
Pharmacology And Toxicology
Keywords:
SARS-CoV-2; 3CLpro; Novel Mechanism of Catalysis; FDA-approved drugs; Triad
Online: 7 May 2024 (16:44:24 CEST)
REVIEW
|
doi:10.20944/preprints202309.0353.v1
Subject:
Medicine And Pharmacology,
Pharmacology And Toxicology
Keywords:
FDA; Omics technology; Pharmacodynamic biomarkers; biosimilars; Proteomics; Gycomis; Re-ceptor Binding; Pharmacokinetics
Online: 6 September 2023 (03:32:11 CEST)
COMMUNICATION
|
doi:10.20944/preprints202003.0125.v1
Subject:
Medicine And Pharmacology,
Epidemiology And Infectious Diseases
Keywords:
2019-nCoV; Darunavir; ACE-2; Receptor Binding Domain; Metastable Conformation; FDA database
Online: 7 March 2020 (16:28:05 CET)
ARTICLE
|
doi:10.20944/preprints202311.1460.v1
Subject:
Biology And Life Sciences,
Parasitology
Keywords:
Onchocerciasis; drug discovery; anthelmintics; O. gutturosa; motility and MTT inhibition; FDA approved drugs
Online: 23 November 2023 (09:31:11 CET)
REVIEW
|
doi:10.20944/preprints202208.0194.v1
Subject:
Medicine And Pharmacology,
Pharmacology And Toxicology
Keywords:
biosimilar; analytical assessment; animal testing; clinical pharmacology; clinical efficacy; FDA; EMA; MHRA; WHO
Online: 10 August 2022 (05:19:49 CEST)
REVIEW
|
doi:10.20944/preprints202210.0397.v1
Subject:
Public Health And Healthcare,
Health Policy And Services
Keywords:
biosimilars; regulatory process; animal studies; clinical efficacy testing; interchangeability; FDA; EMA; MHRA; MENA; cGMP
Online: 26 October 2022 (03:58:16 CEST)
ARTICLE
|
doi:10.20944/preprints202408.0949.v1
Subject:
Engineering,
Electrical And Electronic Engineering
Keywords:
frequency diverse array (FDA); clutter suppression; space-time adaptive processing (STAP); moving targets detection (MTI)
Online: 14 August 2024 (03:03:43 CEST)
REVIEW
|
doi:10.20944/preprints202401.1357.v1
Subject:
Medicine And Pharmacology,
Medicine And Pharmacology
Keywords:
HIV-1; AIDS; FDA; Combination antiretroviral therapy; latent reservoirs; apoptosis; drug resistance; anti-HIV-1 drug design and discovery
Online: 18 January 2024 (10:29:57 CET)
REVIEW
|
doi:10.20944/preprints202111.0310.v1
Subject:
Computer Science And Mathematics,
Probability And Statistics
Keywords:
Functional Data Analysis (FDA); Hybrid Data; Semi-Functional Partial Linear Regression Model (SFPLR); Partial Functional Linear Regression; Literature Review
Online: 17 November 2021 (15:21:19 CET)
REVIEW
|
doi:10.20944/preprints202306.0380.v1
Subject:
Public Health And Healthcare,
Health Policy And Services
Keywords:
Biosimilars 1; Arab states 1; regulatory guideline 3; harmonization 4; centralized approval 5; EMA 6; FDA 7; Global Medicine Authority (GMA) 8.
Online: 6 June 2023 (08:49:00 CEST)
REVIEW
|
doi:10.20944/preprints202304.1141.v1
Subject:
Medicine And Pharmacology,
Pharmacology And Toxicology
Keywords:
biosimilarity; biosimilars; pharmacodynamic biomarkers; monoclonal antibodies; FDA; clinical efficacy testing in healthy subjects; clinical efficacy testing in patients; functional assays; receptor binding
Online: 28 April 2023 (08:03:20 CEST)
REVIEW
|
doi:10.20944/preprints202302.0030.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
angiogenesis inhibitors; VEGF inhibitors; ovarian cancer; progression-free survival; overall sur-vival; toxicity; systematic review; meta-analysis; randomized controlled trials; FDA approval of cancer drugs
Online: 2 February 2023 (05:26:47 CET)
REVIEW
|
doi:10.20944/preprints202407.1456.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
advanced therapy medicinal products (ATMPs); chimeric antigen receptors (CAR-T cells); B acute lymphoblastic leukaemia (B-ALL); food and drug administration (FDA); systemic lupus erythematosus (SLE); idiopathic inflammatory myositis (IIM); systemic sclerosis (SS); memorial sloan kettering cancer centre (MSKCC); hematopoietic stem cell transplantation [HSCT], non-Hodgkin’ s cell lymphoma (NHCL); multiple myeloma (MM); follicular lymphoma; (FL); large B cell-lymphoma (LBCL); mantle cell lymphoma (MCL); myeloid-derived suppressor cells (MDSCs); rheumatoid arthritis (RA); immune effector cell-associated neurotoxicity syndrome (ICANS); natural killer group member D ligands (NKG2DLs); acute myelogenous leukaemia (AML)
Online: 18 July 2024 (08:03:12 CEST)